Sanofi (SNY) Income towards Parent Company (2009 - 2026)
Sanofi's (SNY) quarterly Income towards Parent Company came in at $30.4 million in Q1 2026, down 83.37% year-on-year from $183.0 million in Q1 2025, and up 100.91% quarter-over-quarter from -$3.3 billion in Q4 2025.
Sanofi (SNY) Income towards Parent Company (2009 - 2026) Analysis & Trends
Sanofi has disclosed Income towards Parent Company across 18 years of filings, most recently posting $30.4 million for Q1 2026.
- Income towards Parent Company for Q1 2026 came in at $30.4 million, down 83.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 3539.21% YoY), and the FY2025 annual result was $9.1 billion, up 53.07% from the prior year.
- Income towards Parent Company came in at $30.4 million for Q1 2026 at Sanofi, up from -$3.3 billion in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $6.7 billion in Q4 2022 to a low of -$3.3 billion in Q4 2025.
- The 5-year median for Income towards Parent Company is $1.8 billion (2022), against an average of $1.7 billion.
- Peak annual rise in Income towards Parent Company reached 7513.84% in 2025, while the deepest fall reached 1655.15% in 2025.
- Sanofi's Income towards Parent Company stood at $6.7 billion in 2022, then sank by 107.07% to -$472.3 million in 2023, then soared by 59.73% to -$190.2 million in 2024, then plunged by 1655.15% to -$3.3 billion in 2025, then jumped by 100.91% to $30.4 million in 2026.
- The last three Income towards Parent Company figures came in at $30.4 million (Q1 2026), -$3.3 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Sanofi | 63.47 Mn | -6.87 Bn | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.44 Mn |
| Dec 31, 2025 | -3.34 Bn |
| Sep 30, 2025 | 3.34 Bn |
| Jun 30, 2025 | 3.06 Bn |
| Mar 31, 2025 | 183.03 Mn |
| Dec 31, 2024 | -190.21 Mn |
| Sep 30, 2024 | 43.93 Mn |
| Jun 30, 2024 | 48.46 Mn |
| Mar 31, 2024 | 170.56 Mn |
| Dec 31, 2023 | -472.34 Mn |
| Sep 30, 2023 | 4.45 Bn |
| Jun 30, 2023 | 2.54 Bn |
| Mar 31, 2023 | 3.32 Bn |
| Dec 31, 2022 | 6.68 Bn |
| Sep 30, 2022 | 3.46 Bn |
| Jun 30, 2022 | 1.81 Bn |
| Mar 31, 2022 | 3.16 Bn |
| Dec 31, 2021 | 289.88 Mn |
| Sep 30, 2021 | 4.39 Bn |
| Jun 30, 2021 | 2.29 Bn |